The total return over the past 12 months is -12.18% vs. +16.94% for the S&P 500. So far it's up +5.90% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (12.18%) | +1.43% | (49.61%) | N/A | N/A | N/A |
| Total Return CAGR | (12.18%) | +1.43% | (49.61%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
NRx Pharmaceuticals, Inc. (NRXP)
| Year | Start price | End price | NRXP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.71 | $2.87 | +5.90% | +14.51% | (8.61%) |
| 2025 | $2.20 | $2.71 | +23.18% | +17.72% | +5.46% |
| 2024 | $4.60 | $2.20 | (52.17%) | +24.89% | (77.06%) |
| 2023 | $11.10 | $4.60 | (58.56%) | +26.19% | (84.75%) |
| 2022 | $47.80 | $11.10 | (76.78%) | (18.17%) | (58.61%) |
| 2021 | $244.00 | $47.80 | (80.41%) | +28.74% | (109.15%) |
| 2020 | $106.00 | $244.00 | +130.19% | +18.37% | +111.82% |
| 2019 | $102.00 | $106.00 | +3.92% | +31.22% | (27.30%) |
| 2018 | $96.80 | $102.00 | +5.37% | (4.56%) | +9.93% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
